REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 493 participants.
Also called NCT01483560
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 493 participants
- Sponsor
- Registry
-
NCT01483560 -
2011-000300-18
-
- Other papers using this trial's data
- Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Canada, Denmark, Netherlands, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01483560. Randomized; triple masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2017-03-19 (actual). Results posted on 2019-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
- Acronym
- REMOVAL
- Condition
- Diabetes Mellitus, Type 1
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Glasgow
- Collaborator
- NHS Greater Glasgow and Clyde
- Collaborator
- Juvenile Diabetes Research Foundation
- Collaborator
- Imperial College London
- Collaborator
- University of Wisconsin, Madison
- Collaborator
- University of Dundee
- Collaborator
- Merck Serono S.A., Geneva
- Collaborator
- Itamar-Medical, Israel
- Collaborator
- University of Western Ontario, Canada
- Collaborator
- University of Melbourne
- Collaborator
- Steno Diabetes Center Copenhagen
- Collaborator
- Maastricht University Medical Center
Record details
- Record id
cardio:ct-nct01483560- Content hash
82ddd3452dad7d834adfc3363dc909ab19d850e810ab5028a7d816b1c5fc73bd